Enzon Pharmaceuticals (ENZN)

Enzon Pharmaceuticals (ENZN) Income Statement


Enzon Pharmaceuticals Income Statement

Last quarter (Q2 2023), Enzon Pharmaceuticals's total revenue was $―, a decrease of ― from the same quarter last year. In Q2, Enzon Pharmaceuticals's net income was $-348.00K. See Enzon Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
$ 26.00K$ 26.00K$ 701.00K$ 52.00K$ 207.00K$ 6.92M
Cost of Revenue
Gross Profit
$ 26.00K$ 26.00K----
Operating Expense
$ 1.06M$ -1.06M$ 1.17M$ 1.36M$ 1.18M$ 1.06M
Operating Income
$ -1.03M$ -1.03M$ -469.00K$ -1.30M$ -973.00K$ 5.86M
Net Non Operating Interest Income Expense
Other Income Expense
$ -138.00K$ -646.00K$ 7.00K$ 1.00K--
Pretax Income
$ 519.00K$ -386.00K$ -462.00K$ -1.30M$ -973.00K$ 5.86M
Tax Provision
$ -179.00K$ -200.00K$ 7.00K$ 7.00K$ 6.00K$ 6.00K
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ -577.00K$ -1.46M$ -2.49M$ -1.77M$ -979.00K$ 5.85M
Basic EPS
-$ -0.02$ -0.03$ -0.03$ -0.02$ 0.13
Diluted EPS
-$ -0.02$ -0.03$ -0.03$ -0.02$ 0.13
Basic Average Shares
$ 74.44M$ 74.22K$ 74.22M$ 51.10M$ 44.22M$ 44.22M
Diluted Average Shares
$ 74.44M$ 74.22K$ 74.22M$ 51.10M$ 44.22M$ 44.22M
Dividend Per Share
--$ 0.00$ 0.00$ 0.12-
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
$ 1.06M$ -1.06M$ 1.17M$ 1.36M$ 1.18M$ 1.06M
Net Income From Continuing And Discontinued Operation
$ 698.00K$ -186.00K$ -469.00K$ -1.31M$ -979.00K$ 5.85M
Normalized Income
$ 170.65K-$ -469.00K$ -1.31M$ -979.00K$ 5.85M
Interest Expense
$ 311.00K$ -386.00K$ -469.00K$ -1.30M$ -973.00K$ 5.86M
$ 76.00K$ -386.00K$ -469.00K$ -1.30M$ -973.00K$ 5.86M
Currency in USD

Enzon Pharmaceuticals Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis